Cut through the noise.
Trade on the signal.

A weekly synthesis of institutional-grade financial reports and market mechanics.

No spam. Unsubscribe anytime.

All Reports Clinical Trial Data × / Market Intelligence

Clinical Trial Data

1 of 1 reports

TERN —

—

TERN Terns Pharmaceuticals

Merck’s $5.7B Terns Bet Rests on 38 Patients: Does TERN-701 Justify the Price Over Asciminib?

Two Natural Capital argues Merck's bid isn't obviously cheap -- the merger process showed two bidders wouldn't top Terns' market price and a third walked away after seeing updated trial data showing lower MMR rates th...

Two Natural Capital

Apr 8, 2026

Cut through the noise.Trade on the signal.

Clinical Trial Data

Merck’s $5.7B Terns Bet Rests on 38 Patients: Does TERN-701 Justify the Price Over Asciminib?

The Signal. No Noise.

Cut through the noise.
Trade on the signal.